EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieMultizentrische StudieOpen Access

Letrozole and Infertility Among Males With Spermatogenic Failure

Yifan Sun, Chencheng Yao, Gang Liu, Zheng Li, Xiaoyu Yang, Qigui Chen, Zhen Ye, Honggang Li, Xiaowei Qu, Haibin Guo, Jun Yang, Tao Wang und 18 weitere

JAMA Network Open · 18.06.2026 · 9 (6) · e2618422

DOI: 10.1001/jamanetworkopen.2026.18422 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift JAMA Network Open, online erschienen am 18.06.2026. Verfasst von Yifan Sun und 29 weiteren Autor:innen. Beteiligte Einrichtung: Department of Andrology, the Center for Men's Health, Urologic Medical Center, Shanghai Key Laboratory of Reproductive Medicine, Shanghai General Hos…. Hauptthemen laut MEDLINE: Letrozole, Infertility, Male, Aromatase Inhibitors. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Importance Spermatogenic failure (SPGF) is a severe form of male infertility with limited evidence-based medical treatment options. Aromatase inhibitors represent a promising therapeutic strategy for SPGF, but high-quality evidence is lacking.

Objective

To evaluate the efficacy and safety of letrozole for improving sperm concentration categories in men with SPGF. Design, Setting, and Participants This multicenter, open-label, assessor-blinded randomized clinical trial was conducted at 10 male infertility centers in China from July 2023 to March 2024. Men with SPGF (nonobstructive azoospermia [NOA], cryptozoospermia, or severe oligozoospermia) were enrolled. Follow-up for the primary outcome was completed in June 2024. Data were analyzed from July 2024 to March 2025.

Interventions

Participants were randomized to receive letrozole (2.5 mg daily) plus vitamins C and E or vitamins C and E alone (control group) for 3 months. Main Outcomes and Measures The primary outcome was World Health Organization Sperm Concentration Categories (WHO-SCC) upgrade rate at 3 months after randomization. The secondary outcomes were WHO-SCC grades, Dutch Society of Obstetrics and Gynecology Total Motile Sperm Count Categories (NVOG-TMSCC) upgrade rate, semen parameters, and reproductive hormone levels.

Results

Among 296 participants (mean [SD] age, 30.2 [3.9] years; 218 [73.6%] with NOA; 147 randomized to the letrozole group and 149 to the control group), 247 (83.4%) completed the trial, and all 296 were included in the primary analysis. WHO-SCC upgrade rates were 14.3% (21 of 147 participants) with letrozole vs 5.4% (8 of 149 participants) with control (risk difference, 9.2% [95% CI, 2.5%-15.8%]; P = .01). Participants in the letrozole group had higher odds of achieving a better WHO-SCC grade than those in the control group (common odds ratio, 2.65 [95% CI, 1.28-5.47]; P = .008). The NVOG-TMSCC upgrade rate was also higher with letrozole. Letrozole significantly increased serum gonadotropins and testosterone while decreasing estradiol. There were no significant between-group differences in semen parameters. Decreased libido (18 [12.2%] vs 8 [5.4%]; P = .04) was more frequent with letrozole than with control. Conclusions and Relevance In this randomized clinical trial of men with spermatogenic failure, letrozole significantly improved sperm concentration categories and was well tolerated, supporting its use as an option to downstage infertility severity and potentially enable less invasive reproductive management. Trial Registration chictr.org.cn Identifier: ChiCTR2300073861

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

LetrozoleInfertility, MaleAromatase InhibitorsHumansMaleAdultSperm CountChinaSpermatogenesisAzoospermiaTreatment Outcome

Substanzen

LetrozoleAromatase Inhibitors

Autor:innen und Institutionen

  • Department of Andrology, the Center for Men's Health, Urologic Medical Center, Shanghai Key Laboratory of Reproductive Medicine, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, Chi…
  • Department of Andrology, The Reproductive Hospital of Guangxi Zhuang Autonomous Region, Nanning, Guangxi, China.
  • State Key Laboratory of Reproductive Medicine and Offspring Health, Clinical Center of Reproductive Medicine, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
  • Center for Reproductive Medicine, Wuhan Children's Hospital: Wuhan Women and Children Medical Care Center, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China.
  • Wuhan Huake Reproductive Hospital, Wuhan, Hubei, China.
  • Institute of Reproductive Health, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China.

Zitieren

APA

Sun, Y., Yao, C., Liu, G., Li, Z., Yang, X., Chen, Q., Ye, Z., Li, H., Qu, X., Guo, H., Yang, J., Wang, T., Liang, G., Zhu, X., Lu, Y., Chen, W., Zhang, F., Tian, R., Zhi, E., …, & Li, P. (2026). Letrozole and Infertility Among Males With Spermatogenic Failure. JAMA Network Open, 9(6), e2618422. https://doi.org/10.1001/jamanetworkopen.2026.18422

Vancouver

Sun Y, Yao C, Liu G, Li Z, Yang X, Chen Q, et al. Letrozole and Infertility Among Males With Spermatogenic Failure. JAMA Network Open. 2026;9(6):e2618422. doi:10.1001/jamanetworkopen.2026.18422

BibTeX
@article{Sun2026,
  author = {Sun, Yifan and Yao, Chencheng and Liu, Gang and Li, Zheng and Yang, Xiaoyu and Chen, Qigui and Ye, Zhen and Li, Honggang and Qu, Xiaowei and Guo, Haibin and Yang, Jun and Wang, Tao and Liang, Guoqing and Zhu, Xiaobin and Lu, Yichang and Chen, Weikang and Zhang, Fengbin and Tian, Ruhui and Zhi, Erlei and Chen, Huirong and Zhao, Fujun and Bai, Furong and Sun, Hongfang and Zhang, Jianxiong and Bu, Xinjie and Qian, Dewei and Wu, Sicheng and Qiu, Yan and Li, Zheng and Li, Peng},
  title = {Letrozole and Infertility Among Males With Spermatogenic Failure},
  journal = {JAMA Network Open},
  year = {2026},
  volume = {9},
  number = {6},
  pages = {e2618422},
  doi = {10.1001/jamanetworkopen.2026.18422}
}
Kostenlos starten →